Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers due to high metastatic potential and already advanced stages at diagnosis. Only 20% of patients receive curative-intent surgery, followed by adjuvant chemotherapy, and another 20% with locally advanced disease are evaluated for secondary resection after neoadjuvant chemotherapy. Just one third of patients respond to chemotherapy and reliable biomarkers for response prediction are still missing. PDAC tumors display a wide heterogeneity, including different subtypes with distinct genetic signatures.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
